system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, RESULTS. Meshes: Arsenic Trioxide, Arsenicals, Cell Death, Cell Line, Tumor, Chromosomes, Human, Pair 3, Female, Gene Dosage, Gene Expression Regulation, Neoplastic, Gene Knockdown Techniques, Humans, Interferon-alpha, Intracellular Signaling Peptides and Proteins, Ovarian Neoplasms, Oxides, Phospholipid Transfer Proteins, Proto-Oncogene Proteins, RNA Interference, RNA, Messenger.
user
Is phospholipid Scramblase 1 , an interferon-regulated gene located at 3q23 , regulated by SnoN/SkiL in ovarian cancer cells? Context: Treatment of advanced stage ovarian cancer continues to be challenging due to acquired drug resistance and lack of early stage biomarkers. Genes identified to be aberrantly expressed at the 3q26.2 locus (i.e. SnoN/SkiL) have been implicated in ovarian cancer pathophysiology. We have previously shown that SnoN expression is increased in advanced stage ovarian cancers and alters cellular response to arsenic trioxide (As2O3). We now demonstrate increased DNA copy number levels (TCGA data) of phospholipid scramblase 1 (PLSCR1, located at 3q23) whose transcript expression in ovarian cell lines is highly correlated with SnoN mRNA. Interestingly, SnoN can modulate PLSCR1 mRNA levels in the absence/presence of interferon (IFN-2α). Both IFN-2α and As2O3 treatment can modulate PLSCR1 mRNA levels in ovarian carcinoma cells. However, SnoN siRNA does not lead to altered PLSCR1 protein implicating other events needed to modulate its protein levels. In addition, we report that PLSCR1 can modulate aspects of the As2O3 cellular response.
assistant
Our findings warrant further investigation into the role of PLSCR1 in ovarian cancer development and chemoresistance. Final Decision: yes